IRIS
RUGGIERI, Maddalena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.408
AS - Asia 2.625
EU - Europa 2.481
SA - Sud America 737
Continente sconosciuto - Info sul continente non disponibili 186
AF - Africa 144
OC - Oceania 4
Totale 13.585
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.199
SG - Singapore 1.129
IT - Italia 880
CN - Cina 597
BR - Brasile 582
HK - Hong Kong 304
SE - Svezia 286
RU - Federazione Russa 265
DE - Germania 237
UA - Ucraina 204
VN - Vietnam 175
FR - Francia 170
FI - Finlandia 159
GB - Regno Unito 115
CA - Canada 88
IN - India 87
BD - Bangladesh 74
CI - Costa d'Avorio 62
AR - Argentina 44
JP - Giappone 37
ID - Indonesia 35
MX - Messico 34
IQ - Iraq 31
TR - Turchia 28
VE - Venezuela 27
EC - Ecuador 26
ES - Italia 24
ZA - Sudafrica 23
IE - Irlanda 21
BE - Belgio 20
CO - Colombia 20
PH - Filippine 20
PK - Pakistan 20
PL - Polonia 20
NL - Olanda 19
AT - Austria 13
LT - Lituania 13
CR - Costa Rica 12
PY - Paraguay 12
SA - Arabia Saudita 12
TT - Trinidad e Tobago 12
CW - ???statistics.table.value.countryCode.CW??? 11
NI - Nicaragua 11
TN - Tunisia 11
UZ - Uzbekistan 11
JO - Giordania 10
KE - Kenya 10
GT - Guatemala 9
MA - Marocco 9
SV - El Salvador 9
CL - Cile 8
EG - Egitto 8
HN - Honduras 8
IL - Israele 8
IR - Iran 8
JM - Giamaica 8
SC - Seychelles 8
MY - Malesia 7
PE - Perù 7
AE - Emirati Arabi Uniti 6
CZ - Repubblica Ceca 6
PR - Porto Rico 6
PT - Portogallo 5
UY - Uruguay 5
BO - Bolivia 4
CH - Svizzera 4
DO - Repubblica Dominicana 4
OM - Oman 4
AL - Albania 3
AO - Angola 3
AU - Australia 3
DK - Danimarca 3
NP - Nepal 3
PS - Palestinian Territory 3
TH - Thailandia 3
AZ - Azerbaigian 2
BG - Bulgaria 2
GP - Guadalupe 2
HR - Croazia 2
KR - Corea 2
KZ - Kazakistan 2
PA - Panama 2
RO - Romania 2
RS - Serbia 2
SN - Senegal 2
BB - Barbados 1
BF - Burkina Faso 1
BJ - Benin 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
BZ - Belize 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
GH - Ghana 1
GM - Gambi 1
GR - Grecia 1
GY - Guiana 1
Totale 13.397
Salva come PNG Salva come JPEG
Città #
Ashburn 754
Singapore 591
San Jose 541
Chandler 522
Fairfield 500
Woodbridge 473
Jacksonville 454
Hong Kong 304
Houston 268
Milan 268
Nyköping 220
Ann Arbor 214
Wilmington 198
Seattle 183
Beijing 172
Cambridge 171
Council Bluffs 164
Los Angeles 127
Lawrence 107
Roxbury 103
Nanjing 102
Lauterbourg 101
Bari 97
New York 96
Dallas 93
Rome 86
Boardman 76
Des Moines 69
Santa Clara 67
Chicago 66
Abidjan 62
Columbus 58
Helsinki 56
Ho Chi Minh City 54
Brooklyn 49
Munich 48
Buffalo 47
São Paulo 43
Inglewood 42
North Bergen 42
Princeton 41
Marseille 33
Hanoi 31
Tokyo 31
Salt Lake City 29
San Diego 29
Nanchang 25
Rio de Janeiro 24
Figino 23
Jiaxing 23
Shenyang 23
Moscow 22
Toronto 22
Frankfurt am Main 21
Brussels 20
Tianjin 20
Turin 20
Falkenstein 19
Montreal 19
Dublin 18
Hebei 18
Miami 18
Belo Horizonte 17
Chennai 17
Clifton 17
Jakarta 17
Warsaw 17
Phoenix 16
San Francisco 15
Bologna 14
Mexico City 14
Naples 14
Orem 14
Dearborn 13
London 13
Nuremberg 13
Secaucus 13
Denver 12
Elk Grove Village 12
Johannesburg 12
Mottola 12
Norwalk 12
Pittsburgh 12
Pune 12
Tampa 12
Atlanta 11
Augusta 11
Baghdad 11
Da Nang 11
Stockholm 11
Tashkent 11
Willemstad 11
Caracas 10
Dong Ket 10
El Paso 10
Guangzhou 10
Haiphong 10
Managua 10
Newark 10
San José 10
Totale 8.694
Salva come PNG Salva come JPEG
Nome #
Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis 380
Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Potential Diagnostic Biomarkers in Autism Spectrum Disorders: A Preliminary Study 295
Clinical, histologic and prognostic features of clinically amyopathic dermatomyositis 202
Anti-SAE dermatomyositis: clinical and histologic characteristics from a monocentric Italian cohort 200
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. 195
Age-related changes of serum N-acetyl-aspartate in healthy controls. 194
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 187
Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies 183
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 182
Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis 179
Cerebrospinal Fluid and Clinical Profiles in Adult Type 2–3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience 176
IMMUNOPATOLOGIA DELLA SCLEROSI MULTIPLA 175
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of Multiple Sclerosis 171
Cerebrospinal fluid analysis and the determination of oligoclonal bands 169
Development of an aquaporin-4 orthogonal array of particle-based ELISA for neuromyelitis optica autoantibodies detection 168
IFNβ enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism 165
ANTINFLAMMATORY EFFECTS OF RIFNB-1B IN MULTIPLE SCLEROSIS: LONGITUDINAL CHANGES OF THE SERUM SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 (SICAM-1), TNFA AND T-CELL SUBSETS 164
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 164
Glatiramer Acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from Multiple Sclerosis patients 158
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. 156
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment 156
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels 154
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 150
B and T Immunoregulation: A New Insight of B Regulatory Lymphocytes in Autism Spectrum Disorder 141
Is cerebrospinal fluid amyloid-β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients? 138
A population-based surveillance Italian study of Interferon beta treatment in Multiple Sclerosis patients: relationships between neutralizing antibodies production and clinical outcomes 137
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 134
Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD) 130
Beta Amyloid 1-40 peptide selectively downregulates MMP-9 production in differentiated SH-SY5Y neuronal cell line 129
Serum levels of N-acetylaspartate in Huntington's disease: Preliminary results. 129
ADHESION MOLECULES AND MATRIX METALLOPROTEINASES IN MS: EFFECTS INDUCED BY INTERFERON BETA 129
Antinflammatory effects of rIFNb-1b in multiple sclerosis: longitudinal changes of the serum soluble Intercellular Adhesion Molecule-1 (sICAM-1), TNFa and T-cell subsets 128
CHANGES OF NAIVE AND EFFECTOR/MEMORY T-CELL SUBSETS AND SERUM SOLUBLE ICAM-1 INDUCED BY RIFNB-1B IN MS 127
Identification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding 127
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. 126
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 125
Analisi fenotipica di linfociti T di pazienti con Sclerosi Multipla (SM) nel sangue periferico ed in coltura con e senza aggiunta di mitogeni 125
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 124
Autophagy increase in Merosin-Deficient Congenital Muscular Dystrophy type 1A 123
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes 121
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica 121
Serum levels of N-acetyl-aspartate in migraine and tension-type headache. 121
A LONGITUDINAL ANALYSIS OF SERUM SOLUBLE ICAM-1 (SICAM-1), TNFA AND T-CELL SUBSETS IN MULTIPLE SCLEROSIS (MS) PATIENTS DURING RIFNB-1B TREATMENT 120
Neurofilament ELISA validation 119
Serum levels of N-acetyl-aspartate in migraine and tension-type headache. 117
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 116
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. 115
Correlations between neutralizing antibodies production and clinical outcomes: analysis in a population-based surveillance italian study of interferon beta treatment in multiple sclerosis patients 113
Decreased levels of serum Gelatinase B in MS patients treated with rIFN-beta-1b 112
Cerebrospinal Fluid and Serum Neurofilament Light Chain Levels in ALS Patients 112
ANALISI DEL POLIMORFISMO GENICO E DELLA PRODUZIONE LIMFOMONOCITARIA DI TNF-ALPHA IN PAZIENTI CON SCLEROSI MULTIPLA (SM) 112
MMP-9 and 2 activities and TIMPs in MS: differences between early and chronic disease 111
Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients 110
Plasma pentraxin 3 in idiopathic inflammatory myopathies: a possible new biomarker of disease activity 109
CHANGES OF SERUM SOLUBLE ICAM-1 AND MATRIX METALLOPROTEINASE-9 DURING INTERFERON BETA-1B TREATMENT IN RR MS 109
Elevated Expression of ADAM10 in Skeletal Muscle of Patients with Idiopathic Inflammatory Myopathies Could Be Responsible for FNDC5/Irisin Unbalance 109
Italian studies on early-onset multiple sclerosis: the present and the future 107
Glatiramer acetate in multiple sclerosis: a review 107
CHANGES OF SERUM ICAM-1 AND MMP-9 INDUCED BY RIFNB-1B TREATMENT IN RELAPSING-REMITTING MS 106
Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients 103
Bcl-2, Bax, Cytocrome-c mitochondria mediated apoptosis proteins during Glatiramer Acetate treatment in Multiple Sclerosis patients 103
Serum Soluble ICAM-1 and Gelatinase B Novel Markers of Clinical Efficacy of the RIFN-beta-1b in Relapsing-Remitting Multiple Sclerosis 102
Neutralizing antibodies during treatment of relapsing Multiple Sclerosis patients with three interferon beta: correlation with clinical outcomes 100
Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis 100
UN ANNO DI TRATTAMENTO CON INTERFERONE B-1B INCREMENTA I LIVELLI SIERICI DI SICAM-1 E RIPRISTINA LA FUNZIONE SOPPRESSORIA DEI T-LINFOCITI IN PAZIENTI CON SM RELAPSING-REMITTING 100
Interferone beta (IFNb) e barriera emato-encefalica nella Sclerosi Multipla: effetto su molecole di adesione e metalloproteasi 100
Serum MMPs and TIMPs in Multiple Sclerosis: differences between early and chronic disease 98
N-Acetyl-Aspartate (NAA) and Neurofilament Light-Chain (NF-L) in Biological Fluids as Markers of Neurodegeneration in ALS 98
Novel anti-inflammatory properties of rIFN-beta-1b in RR MS: recovery of T-suppression and increase of serum sICAM-1 98
Interferon-b treatment in relapsing remitting multiple sclerosis: results of an observational study in southern Italy 97
CHANGES OF SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 (SICAM-1) LEVELS INDUCED BY CORTICOSTEROIDS AND RIFN-BETA-1B IN MULTIPLE SCLEROSIS AND GUILLAIN-BARRÉ SYNDROME 97
Standard (SD) and triple dose (TD) gadolinium (Gd) enhancing lesions are associated with a similar degree of MMP-9 and TIMP-1 involvement at the blood-brain barrier (BBB) level in Multiple Sclerosis (MS) 95
Modificazioni dei livelli sierici di ICAM-1 solubile (sICAM.1), e Gelatinasi A e B e sottopopolazioni T-linfocitarie di sangue periferico indotte dal trattamento con interferone-beta-1b (IFN-BETA-1B) in pazienti con Sclerosi Multipla (SM) Relapsing-Remitting (RR): Relazione con la produzione di anticorpi neutralizzanti anti-interferone (NABs) 94
Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke 94
RIFNB DOWNREGULATES TNFA-INDUCED ICAM-1 EXPRESSION ON BRAIN MICROVASCULAR ENDOTHELIAL CELLS (BEMC) AND INCREASES SERUM SOLUBLE ICAM-1 (SICAM-1) IN RR MS 93
Interferon-b treatment in relapsing remitting multiple sclerosis: results of an observational study in southern Italy 92
Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies 91
Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes 91
Decreased levels of serum gelatinase B in MS patients during the treatment with rIFN-beta-1b 89
STUDIO IN VITRO DI POPOLAZIONI LINFOMONOCITARIE CD45R+ E CD29+ 88
RIFN BETA-1A AND SICAM-1 EFFECTS ON CD4+CD45RO+ PBTLS EXPRESSING LFA-1 IN RR MS: IN VIVO AND IN VITRO STUDY 88
LFA-1 expressing CD4+CD45RO+ peripheral blood T-lymphocytes in RR MS: effects induced by rIFNb-1a 88
Changes of serum soluble ICAM-1 and matrix metalloproteinas-9 (MMP-9) induced by Interferon beta-1b treatment in relapsing-remitting multiple sclerosis 88
Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceutics 86
Changes of serum sICAM-1 and MMP-9 induced by rIFN beta-1b treatment in relapsing-remitting MS 85
LFA-1 EXPRESSION ON CD4+CD45RO+ PERIPHERAL BLOOD T-LYMPHOCYTES: IN VIVO AND IN VITRO CHANGES INDUCED BY RECOMBINANT INTERFERON-BETA-1A (RIFN-BETA-1A) IN RELAPSING-REMITTING (RR) MULTIPLE SCLEROSIS (MS) 84
LFA-1 EXPRESSION ON CD4+CD45RO+ PBTLS DURING RIFN-BETA-1A TREATMENT IN RR MS: IN VIVO AND IN VITRO STUDY 83
Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system 83
MMPs and TIMPs involvement at the blood-brain barrier level in MS: comparison between patients enhancing with different doses of gadolinium during rIFNb-1a treatment 82
VALUTAZIONE POST-MARKETING DI SICUREZZA DELL' INTERFERONE-BETA (IFN-BETA) IN PAZIENTI CON SCLEROSI MULTIPLA (SM) RELAPSING-REMITTING (RR) NELL' ITALIA MERIDIONALE. RICERCA SCIENTIFICA DELLE 81
Serum N-acetyl-aspartate in Relapsing Remitting Multiple Sclerosis 81
IFNB-1B TREATMENT EFFECTS ON SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 SERUM LEVELS AND T-CELL SUBSETS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS. 12TH CONGRESS OF THE EUROPEAN COMMITTE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) 80
MMPS AND TIMPS ARE DIFFERENTLY RELATED TO MS COURSES AND PHASES OF THE DISEASE 80
Matrix metalloproteinases and disease corse in Multiple Sclerosis 79
Soluble Intercellular Adhesion Molecule-1 in serum and cerebrospinal fluid of demyelinating disease of the central and peripheral nervous system 78
NMO-IgG and AQP-4 antibodies in different demyelinating disease phenotypes: correlations with clinical and paraclinical parameters 78
SOPLUBLE INTERCELLULAR ADHESION MOLECULE-1 (SICAM-1) NEL SIERO E LIQUOR DI PAZIENTI CON SCLEROSI MULTIPLA REMITTENTE CLINICAMENTE ATTIVA: CORRELAZIONI CON LESIONI RMI CHE ASSUMONO GADOLINIO E CON PARAMETRI LIQUORALI 76
CSF and serum soluble adhesion molecules in Multiple Sclerosis 76
CHANGES OF SICAM-1, TNFA AND T-CELL SUBSETS IN THE BLOOD OF MULTIPLE SCLEROSIS PATIENTS DURING RIFNB-1B TREATMENT. GRUPPO ITALIANO PER LO STUDIO DELLA NEUROMORFOLOGIA 73
null 72
Totale 12.306
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.020
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.020
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022501 0 0 0 0 25 35 28 42 40 21 135 175
2022/20231.298 172 121 83 133 157 176 11 145 234 1 30 35
2023/2024391 47 70 24 24 24 90 28 21 4 10 3 46
2024/20252.092 62 36 146 55 46 152 155 187 67 129 443 614
2025/20264.330 621 206 286 453 458 241 459 135 421 410 135 505
2026/20271.308 269 178 363 494 4 0 0 0 0 0 0 0
Totale 13.585